Research & Educational Disclaimer
This content is for research and educational purposes only and does not constitute medical advice. Consult a qualified healthcare professional before making health decisions.
Few therapeutic classes have undergone as remarkable a scientific evolution as the GLP-1 receptor agonists. What began as a treatment for glycaemic control in type 2 diabetes has, over three decades of research, become one of the most significant advances in obesity pharmacotherapy. Understanding this history — and the policy implications it carries — is essential context for anyone engaged with contemporary metabolic health research.
The Biology of GLP-1
Glucagon-like peptide-1 is an incretin hormone secreted by L-cells in the distal small intestine and colon in response to nutrient ingestion. First characterised in the 1980s, GLP-1 was recognised for its glucose-dependent insulinotropic effects: it stimulates insulin secretion and suppresses glucagon release, but only when blood glucose is elevated. This glucose-dependency is clinically important — it substantially reduces the risk of hypoglycaemia compared to older insulin secretagogues.
GLP-1 also acts centrally. Receptors in the hypothalamus and brainstem respond to GLP-1 signalling by suppressing appetite, slowing gastric emptying, and reducing food intake. These central effects, observed in early rodent studies, hinted at a therapeutic potential well beyond glycaemic control — a potential that would take decades to fully realise in humans.
Daniel Drucker and colleagues published foundational work on the biology of incretin hormones that established GLP-1 as a multifunctional metabolic regulator (PMID: 16467221). This scientific groundwork was essential to the clinical development that followed.
From Exenatide to Semaglutide: A Progression
The first GLP-1 receptor agonist approved for clinical use was exenatide, introduced in 2005. Derived from a peptide found in Gila monster saliva (exendin-4), exenatide required twice-daily subcutaneous injection and produced modest reductions in HbA1c and body weight. Its clinical significance lay less in its magnitude of effect and more in what it demonstrated: that pharmacological GLP-1 receptor activation was feasible, tolerable, and associated with weight loss — a finding that directed subsequent research.
Liraglutide, a once-daily human GLP-1 analogue with 97% sequence homology to endogenous GLP-1, showed improved weight loss profiles compared to exenatide. Crucially, when studied at higher doses specifically for obesity (rather than diabetes) in the SCALE trials, liraglutide 3.0 mg produced clinically meaningful weight reductions — marking the first formal step toward GLP-1 therapy as an obesity treatment.
Semaglutide represented a further leap. With a half-life supporting once-weekly dosing, and a structural modification enabling higher bioavailability, semaglutide demonstrated weight reductions of approximately 15% in the STEP-1 trial — results that significantly exceeded anything previously seen in pharmacological obesity research.
The Policy Dimension
The clinical progression of GLP-1 therapy raises important policy questions that extend beyond pharmacology. Access, affordability, and equitable prescribing are central concerns in the Australian context.
For a condition as prevalent as obesity, the therapeutic pipeline must be matched by a regulatory and reimbursement framework that ensures access for those who would benefit most clinically. Currently, PBS listing arrangements create gaps between what is available in clinical trials and what is accessible to Australian patients in routine care. For a detailed policy analysis of what PBS reform should look like — including proposed criteria for GLP-1 access, prescriber frameworks, and equity considerations — see our Medicare and PBS reform for obesity treatment policy analysis.
Understanding this policy landscape is important context for reading the obesity crisis in Australia — because the biology of effective treatment is only part of the equation. It is also worth noting that GLP-1 receptor agonists like semaglutide and tirzepatide are Schedule 4 medicines in Australia, meaning access is governed by the TGA's prescription framework; for a full breakdown of how that framework operates across both approved and unapproved peptide compounds, see our TGA peptide regulation guide for patients and clinicians. The metabolic syndrome population — in whom GLP-1 agents address multiple syndrome components simultaneously — is particularly underserved by current PBS criteria; see our metabolic syndrome public health policy analysis for the full policy case.
GLP-1 Beyond Weight: Cardiovascular and Renal Research
A consistent finding across GLP-1 receptor agonist trials has been evidence of cardiovascular benefit independent of weight loss. The LEADER trial (liraglutide) and SUSTAIN-6 trial (semaglutide) both demonstrated significant reductions in major adverse cardiovascular events in high-risk patients with type 2 diabetes.
This finding shifted how the field understood GLP-1 receptor agonists: not merely as tools for glycaemic or weight management, but as agents with pleiotropic metabolic effects. The cardiovascular data contributed substantially to regulatory approval processes and to the argument for broader therapeutic use.
Ongoing research is exploring GLP-1 effects on non-alcoholic steatohepatitis (NASH), chronic kidney disease, and neurological outcomes including Alzheimer's disease. This expanding body of evidence reflects the central role of metabolic dysregulation across multiple organ systems.
Transition to Dual and Triple Agonism
The success of GLP-1 receptor agonists created a logical research question: if activating one metabolic receptor produces significant clinical benefit, what might activation of two or three produce? This reasoning led to the development of dual GIP/GLP-1 agonists and, subsequently, triple receptor agonists.
The Australian research community is actively engaging with these therapeutic advances.
For a detailed look at how triple agonism has extended beyond dual GIP/GLP-1 approaches, the research on retatrutide and triple receptor mechanisms documents the current frontier.
Implications for Research and Practice
The evolution from exenatide to contemporary triple receptor agonists represents roughly two decades of iterative scientific advancement. Each generation of therapy has built on a clearer understanding of the biology underlying metabolic disease, and each has progressively improved clinical outcomes.
For the research community, the key task now is translating this scientific progress into equitable access — ensuring that the patients who stand to benefit most are not excluded by cost, geography, or prescribing inertia.
Conclusion
GLP-1 receptor agonists have transformed our understanding of metabolic health. Their journey from a novel diabetes treatment to a cornerstone of obesity pharmacotherapy reflects both the power of mechanistic research and the importance of sustained investment in clinical trials. As the next generation of therapies reaches the research horizon, the foundational science of GLP-1 remains essential reading for anyone engaged with metabolic medicine.